<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33805709</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1420-3049</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Mar</Month><Day>13</Day></PubDate></JournalIssue><Title>Molecules (Basel, Switzerland)</Title><ISOAbbreviation>Molecules</ISOAbbreviation></Journal><ArticleTitle>A Novel Anti-Inflammatory d-Peptide Inhibits Disease Phenotype Progression in an ALS Mouse Model.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1590</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules26061590</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterised by selective neuronal death in the brain stem and spinal cord. The cause is unknown, but an increasing amount of evidence has firmly certified that neuroinflammation plays a key role in ALS pathogenesis. Neuroinflammation is a pathological hallmark of several neurodegenerative disorders and has been implicated as driver of disease progression. Here, we describe a treatment study demonstrating the therapeutic potential of a tandem version of the well-known all-d-peptide RD2 (RD2RD2) in a transgenic mouse model of ALS (SOD1*G93A). Mice were treated intraperitoneally for four weeks with RD2RD2 vs. placebo. SOD1*G93A mice were tested longitudinally during treatment in various behavioural and motor coordination tests. Brain and spinal cord samples were investigated immunohistochemically for gliosis and neurodegeneration. RD2RD2 treatment in SOD1*G93A mice resulted not only in a reduction of activated astrocytes and microglia in both the brain stem and lumbar spinal cord, but also in a rescue of neurons in the motor cortex. RD2RD2 treatment was able to slow progression of the disease phenotype, especially the motor deficits, to an extent that during the four weeks treatment duration, no significant progression was observed in any of the motor experiments. Based on the presented results, we conclude that RD2RD2 is a potential therapeutic candidate against ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Post</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Biological Information Processing, Structural Biochemistry, IBI-7, Forschungszentrum J&#xfc;lich GmbH, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kogel</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute of Biological Information Processing, Structural Biochemistry, IBI-7, Forschungszentrum J&#xfc;lich GmbH, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schaffrath</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Biological Information Processing, Structural Biochemistry, IBI-7, Forschungszentrum J&#xfc;lich GmbH, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lohmann</LastName><ForeName>Philipp</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-5360-046X</Identifier><AffiliationInfo><Affiliation>Institute of Neuroscience and Medicine 4, INM-4, Medical Imaging Physics, Forschungszentrum J&#xfc;lich GmbH, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>N Jon</ForeName><Initials>NJ</Initials><Identifier Source="ORCID">0000-0002-8151-6169</Identifier><AffiliationInfo><Affiliation>Institute of Neuroscience and Medicine 4, INM-4, Medical Imaging Physics, Forschungszentrum J&#xfc;lich GmbH, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neuroscience and Medicine 11, INM-11, JARA, Forschungszentrum J&#xfc;lich GmbH, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>JARA-Brain-Translational Medicine, 52074 Aachen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, RWTH Aachen University, 52062 Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langen</LastName><ForeName>Karl-Josef</ForeName><Initials>KJ</Initials><Identifier Source="ORCID">0000-0003-1101-5075</Identifier><AffiliationInfo><Affiliation>Institute of Neuroscience and Medicine 4, INM-4, Medical Imaging Physics, Forschungszentrum J&#xfc;lich GmbH, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, RWTH Aachen University, 52062 Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willbold</LastName><ForeName>Dieter</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-0065-7366</Identifier><AffiliationInfo><Affiliation>Institute of Biological Information Processing, Structural Biochemistry, IBI-7, Forschungszentrum J&#xfc;lich GmbH, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut f&#xfc;r Physikalische Biologie, Heinrich-Heine-Universit&#xe4;t D&#xfc;sseldorf, 40225 D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willuweit</LastName><ForeName>Antje</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6725-0755</Identifier><AffiliationInfo><Affiliation>Institute of Neuroscience and Medicine 4, INM-4, Medical Imaging Physics, Forschungszentrum J&#xfc;lich GmbH, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kutzsche</LastName><ForeName>Janine</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0271-7390</Identifier><AffiliationInfo><Affiliation>Institute of Biological Information Processing, Structural Biochemistry, IBI-7, Forschungszentrum J&#xfc;lich GmbH, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>20-64-46027</GrantID><Agency>Russian Sciene Foundation</Agency><Country/></Grant><Grant><GrantID>Technology Transfer Fund</GrantID><Agency>Forschungszentrum J&#xfc;lich GmbH</Agency><Country/></Grant><Grant><GrantID>Portfolio Drug Research</GrantID><Agency>Impuls und Vernetzungs-Fonds der Helmholtzgemeinschaft</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Molecules</MedlineTA><NlmUniqueID>100964009</NlmUniqueID><ISSNLinking>1420-3049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050505">Mutant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009842">Oligopeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000656168">RD2 peptide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C109415">SOD1 G93A protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001933" MajorTopicYN="N">Brain Stem</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009048" MajorTopicYN="N">Motor Skills</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050505" MajorTopicYN="N">Mutant Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009842" MajorTopicYN="N">Oligopeptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SOD1*G93A mice</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">behaviour</Keyword><Keyword MajorTopicYN="N">d-enantiomeric peptide</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword></KeywordList><CoiStatement>D.W. is co-inventor of patents covering the composition of matter of RD2RD2. D.W. and A.W. are co-founders and shareholders of the company &#x201c;Priavoid GmbH&#x201d;, which is planning to further develop RD2RD2. Both declare that this did not influence the interpretation of the study results. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>3</Day><Hour>1</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33805709</ArticleId><ArticleId IdType="pmc">PMC7999518</ArticleId><ArticleId IdType="doi">10.3390/molecules26061590</ArticleId><ArticleId IdType="pii">molecules26061590</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cacquevel M., Lebeurrier N., Ch&#xe9;enne S., Vivien D. Cytokines in neuroinflammation and Alzheimer&#x2019;s disease. Curr. Drug Targets. 2004;5:529&#x2013;534. doi: 10.2174/1389450043345308.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389450043345308</ArticleId><ArticleId IdType="pubmed">15270199</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda J., Ji B., Irie T., Tomiyama T., Maruyama M., Okauchi T., Staufenbiel M., Iwata N., Ono M., Saido T.C., et al. Longitudinal, Quantitative Assessment of Amyloid, Neuroinflammation, and Anti-Amyloid Treatment in a Living Mouse Model of Alzheimer&#x2019;s Disease Enabled by Positron Emission Tomography. J. Neurosci. 2007;27:10957&#x2013;10968. doi: 10.1523/JNEUROSCI.0673-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0673-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672864</ArticleId><ArticleId IdType="pubmed">17928437</ArticleId></ArticleIdList></Reference><Reference><Citation>Pgostinho P., Rodrigo A.C., Catarina O. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer&#x2019;s disease. Curr. Pharm. Des. 2010;16:2766&#x2013;2778. doi: 10.2174/138161210793176572.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161210793176572</ArticleId><ArticleId IdType="pubmed">20698820</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka M.T., Carson M.J., El Khoury J., E Landreth G., Brosseron F., Feinstein D.L., Jacobs A.H., Wyss-Coray T., Vitorica J., Ransohoff R.M., et al. Neuroinflammation in Alzheimer&#x2019;s disease. Lancet Neurol. 2015;14:388&#x2013;405. doi: 10.1016/S1474-4422(15)70016-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(15)70016-5</ArticleId><ArticleId IdType="pmc">PMC5909703</ArticleId><ArticleId IdType="pubmed">25792098</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell J., Borasio G. Amyotrophic lateral sclerosis. Lancet. 2007;369:2031&#x2013;2041. doi: 10.1016/S0140-6736(07)60944-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)60944-1</ArticleId><ArticleId IdType="pubmed">17574095</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland D.W., Rothstein J.D. From charcot to lou gehrig: Deciphering selective motor neuron death in als. Nat. Rev. Neurosci. 2001;2:806&#x2013;819. doi: 10.1038/35097565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35097565</ArticleId><ArticleId IdType="pubmed">11715057</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H.X., Hentati A., A Tainer J., Iqbal Z., Cayabyab A., Hung W.Y., Getzoff E.D., Hu P., Herzfeldt B., Roos R.P., et al. Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase. Science. 1993;261:1047&#x2013;1051. doi: 10.1126/science.8351519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8351519</ArticleId><ArticleId IdType="pubmed">8351519</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P.C., Hentati A., Donaldson D.H., Goto J., O&#x2019;Regan J.P., Deng H.-X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M.E. The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J. Neurol. Sci. 1997;152:s67&#x2013;s73. doi: 10.1016/S0022-510X(97)00247-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(97)00247-5</ArticleId><ArticleId IdType="pubmed">9419057</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Sharma K., Deng H.-X., Siddique T., Grisotti G., Liu E., Roos R.P. Restricted expression of mutant SOD1 in spinal motor neurons and interneurons induces motor neuron pathology. Neurobiol. Dis. 2008;29:400&#x2013;408. doi: 10.1016/j.nbd.2007.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2007.10.004</ArticleId><ArticleId IdType="pubmed">18054242</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;zdinler P.H., Benn S., Yamamoto T.H., G&#xfc;zel M., Brown R.H., Macklis J.D. Corticospinal Motor Neurons and Related Subcerebral Projection Neurons Undergo Early and Specific Neurodegeneration in hSOD1G93A Transgenic ALS Mice. J. Neurosci. 2011;31:4166&#x2013;4177. doi: 10.1523/JNEUROSCI.4184-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4184-10.2011</ArticleId><ArticleId IdType="pmc">PMC3643523</ArticleId><ArticleId IdType="pubmed">21411657</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein J.D. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol. 2009;65:S3&#x2013;S9. doi: 10.1002/ana.21543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21543</ArticleId><ArticleId IdType="pubmed">19191304</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T., Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: Role of glial activation in motor neuron disease. Lancet Neurol. 2011;10:253&#x2013;263. doi: 10.1016/S1474-4422(11)70015-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70015-1</ArticleId><ArticleId IdType="pubmed">21349440</ArticleId></ArticleIdList></Reference><Reference><Citation>Robberecht W., Philips T. The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 2013;14:248&#x2013;264. doi: 10.1038/nrn3430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3430</ArticleId><ArticleId IdType="pubmed">23463272</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara J.H., Gen&#xe7; B., Stanford M.J., Pytel P., Roos R.P., Weintraub S., Mesulam M.M., Bigio E.H., Miller R.J., &#xd6;zdinler P.H. Evidence for an early innate immune response in the motor cortex of ALS. J. Neuroinflamm. 2017;14:129. doi: 10.1186/s12974-017-0896-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-017-0896-4</ArticleId><ArticleId IdType="pmc">PMC5485686</ArticleId><ArticleId IdType="pubmed">28651542</ArticleId></ArticleIdList></Reference><Reference><Citation>Boill&#xe9;e S., Yamanaka K., Lobsiger C.S., Copeland N.G., Jenkins N.A., Kassiotis G., Kollias G., Cleveland D.W. Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia. Science. 2006;312:1389&#x2013;1392. doi: 10.1126/science.1123511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1123511</ArticleId><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley K., Abdel-Moaty H., Hunter J., Mhatre M., Mou S., Nguyen K., Potapova T., Pye Q.N., Qi M., Rice H., et al. Primary glia expressing the G93A-SOD1 mutation present a neuroinflammatory phenotype and provide a cellular system for studies of glial inflammation. J. Neuroinflamm. 2006;3:2. doi: 10.1186/1742-2094-3-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-3-2</ArticleId><ArticleId IdType="pmc">PMC1360663</ArticleId><ArticleId IdType="pubmed">16436205</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel N.S., Paris D., Mathura V., Quadros A.N., Crawford F.C., Mullan M.J. Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer&#x2019;s disease. J. Neuroinflamm. 2005;2:9. doi: 10.1186/1742-2094-2-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-2-9</ArticleId><ArticleId IdType="pmc">PMC555557</ArticleId><ArticleId IdType="pubmed">15762998</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka M.T., Kummer M.P., Stutz A., Delekate A., Schwartz S., Vieira-Saecker A., Griep A., Axt D., Remus A., Tzeng T.-C., et al. NLRP3 is activated in Alzheimer&#x2019;s disease and contributes to pathology in APP/PS1 mice. Nat. Cell Biol. 2013;493:674&#x2013;678. doi: 10.1038/nature11729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11729</ArticleId><ArticleId IdType="pmc">PMC3812809</ArticleId><ArticleId IdType="pubmed">23254930</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis C.-A., Manning J., Rossi F., Krieger C. The Neuroinflammatory Response in ALS: The Roles of Microglia and T Cells. Neurol. Res. Int. 2012;2012:1&#x2013;8. doi: 10.1155/2012/803701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/803701</ArticleId><ArticleId IdType="pmc">PMC3362167</ArticleId><ArticleId IdType="pubmed">22666587</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh C.J., Hilton D.J. Negative regulation of cytokine signaling. J. Leukoc. Biol. 2001;70:348&#x2013;356. doi: 10.1189/jlb.70.3.348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.70.3.348</ArticleId><ArticleId IdType="pubmed">11527983</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.D., Nedjai B., Hurst T., Pennington D.J. Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. Biochim. Biophys. Acta. 2014;1843:2563&#x2013;2582. doi: 10.1016/j.bbamcr.2014.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2014.05.014</ArticleId><ArticleId IdType="pubmed">24892271</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott J.L. Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. Mol. Brain Res. 2001;95:172&#x2013;178. doi: 10.1016/S0169-328X(01)00242-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0169-328X(01)00242-X</ArticleId><ArticleId IdType="pubmed">11687290</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer P.L., McGeer E.G. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve. 2002;26:459&#x2013;470. doi: 10.1002/mus.10191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.10191</ArticleId><ArticleId IdType="pubmed">12362410</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeyachandran A., Mertens B., McKissick E.A., Mitchell C.S. Type I Vs. Type II cytokine levels as a function of SOD1 G93A mouse amyotrophic lateral sclerosis disease progression. Front. Cell. Neurosci. 2015;9:462. doi: 10.3389/fncel.2015.00462.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00462</ArticleId><ArticleId IdType="pmc">PMC4664727</ArticleId><ArticleId IdType="pubmed">26648846</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R., Miller R.G., Swash M., Munsat T.L. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R.G., Mitchell J.D., Moore D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst. Rev. 2012;2012:CD001447. doi: 10.1002/14651858.CD001447.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD001447.pub3</ArticleId><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J., Ludolph A.C., Huebers A. Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis. Ther. Adv. Neurol. Disord. 2017;11:1&#x2013;16. doi: 10.1177/1756285617734734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756285617734734</ArticleId><ArticleId IdType="pmc">PMC5784546</ArticleId><ArticleId IdType="pubmed">29399045</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T., Loschwitz J., Strodel B., Nagel-Steger L., Willbold D. Interference with Amyloid-&#x3b2; Nucleation by Transient Ligand Interaction. Molecules. 2019;24:2129. doi: 10.3390/molecules24112129.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules24112129</ArticleId><ArticleId IdType="pmc">PMC6600523</ArticleId><ArticleId IdType="pubmed">31195746</ArticleId></ArticleIdList></Reference><Reference><Citation>Willbold D., Kutzsche J. Do We Need Anti-Prion Compounds to Treat Alzheimer&#x2019;s Disease? Molecules. 2019;24:2237. doi: 10.3390/molecules24122237.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules24122237</ArticleId><ArticleId IdType="pmc">PMC6637388</ArticleId><ArticleId IdType="pubmed">31208037</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutzsche J., J&#xfc;rgens D., Willuweit A., Adermann K., Fuchs C., Simons S., Windisch M., H&#xfc;mpel M., Rossberg W., Wolzt M., et al. Safety and pharmacokinetics of the orally available antiprionic compound PRI-002: A single and multiple ascending dose phase I study. Alzheimer&#x2019;s Dement. Transl. Res. Clin. Interv. 2020;6:e12001. doi: 10.1002/trc2.12001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/trc2.12001</ArticleId><ArticleId IdType="pmc">PMC7087413</ArticleId><ArticleId IdType="pubmed">32211506</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Groen T., Schemmert S., Brener O., Gremer L., Ziehm T., Tusche M., Nagel-Steger L., Kadish I., Schartmann E., Elfgen A., et al. The A&#x3b2; oligomer eliminating d-enantiomeric peptide RD2 improves cognition without changing plaque pathology. Sci. Rep. 2017;7:1&#x2013;12. doi: 10.1038/s41598-017-16565-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-16565-1</ArticleId><ArticleId IdType="pmc">PMC5701182</ArticleId><ArticleId IdType="pubmed">29176708</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutzsche J., Schemmert S., Tusche M., Neddens J., Rabl R., J&#xfc;rgens D., Brener O., Willuweit A., Hutter-Paier B., Willbold D. Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer&#x2019;s Disease. Molecules. 2017;22:1693. doi: 10.3390/molecules22101693.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules22101693</ArticleId><ArticleId IdType="pmc">PMC6151452</ArticleId><ArticleId IdType="pubmed">28994710</ArticleId></ArticleIdList></Reference><Reference><Citation>Schemmert S., Schartmann E., Zafiu C., Kass B., Hartwig S., Lehr S., Bannach O., Langen K.-J., Shah N.J., Kutzsche J., et al. A&#x3b2; Oligomer Elimination Restores Cognition in Transgenic Alzheimer&#x2019;s Mice with Full-blown Pathology. Mol. Neurobiol. 2019;56:2211&#x2013;2223. doi: 10.1007/s12035-018-1209-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1209-3</ArticleId><ArticleId IdType="pmc">PMC6394605</ArticleId><ArticleId IdType="pubmed">30003517</ArticleId></ArticleIdList></Reference><Reference><Citation>Schemmert S., Schartmann E., Honold D., Zafiu C., Ziehm T., Langen K.-J., Shah N.J., Kutzsche J., Willuweit A., Willbold D. Deceleration of the neurodegenerative phenotype in pyroglutamate-A&#x3b2; accumulating transgenic mice by oral treatment with the A&#x3b2; oligomer eliminating compound RD2. Neurobiol. Dis. 2019;124:36&#x2013;45. doi: 10.1016/j.nbd.2018.10.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.10.021</ArticleId><ArticleId IdType="pubmed">30391539</ArticleId></ArticleIdList></Reference><Reference><Citation>Leithold L.H., Jiang N., Post J., Niemietz N., Schartmann E., Ziehm T., Kutzsche J., Shah N.J., Breitkreutz J., Langen K.-J., et al. Pharmacokinetic properties of tandem d-peptides designed for treatment of Alzheimer&#x2019;s disease. Eur. J. Pharm. Sci. 2016;89:31&#x2013;38. doi: 10.1016/j.ejps.2016.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2016.04.016</ArticleId><ArticleId IdType="pubmed">27086111</ArticleId></ArticleIdList></Reference><Reference><Citation>Elfgen A., Hupert M., Bochinsky K., Tusche M., Martin E.G.D.S.R., Gering I., Sacchi S., Pollegioni L., Huesgen P.F., Hartmann R., et al. Metabolic resistance of the d-peptide RD2 developed for direct elimination of amyloid-&#x3b2; oligomers. Sci. Rep. 2019;9:1&#x2013;13. doi: 10.1038/s41598-019-41993-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-41993-6</ArticleId><ArticleId IdType="pmc">PMC6450887</ArticleId><ArticleId IdType="pubmed">30952881</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers D.C., Fisher E.M.C., Brown S.D.M., Peters J., Hunter A.J., Martin J.E. Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment. Mamm. Genome. 1997;8:711&#x2013;713. doi: 10.1007/s003359900551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s003359900551</ArticleId><ArticleId IdType="pubmed">9321461</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers D.C., Peters J., Martin J.E., Ball S., Nicholson S.J., Witherden A.S., Hafezparast M., Latcham J., Robinson T.L., Quilter C.A., et al. SHIRPA, a protocol for behavioral assessment: Validation for longitudinal study of neurological dysfunction in mice. Neurosci. Lett. 2001;306:89&#x2013;92. doi: 10.1016/S0304-3940(01)01885-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(01)01885-7</ArticleId><ArticleId IdType="pubmed">11403965</ArticleId></ArticleIdList></Reference><Reference><Citation>Mead R.J., Bennett E.J., Kennerley A.J., Sharp P., Sunyach C., Kasher P., Berwick J., Pettmann B., Battaglia G., Azzouz M., et al. Optimised and Rapid Pre-clinical Screening in the SOD1G93A Transgenic Mouse Model of Amyotrophic Lateral Sclerosis (ALS) PLoS ONE. 2011;6:e23244. doi: 10.1371/journal.pone.0023244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0023244</ArticleId><ArticleId IdType="pmc">PMC3158065</ArticleId><ArticleId IdType="pubmed">21876739</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings J., Lee G., Ritter A., Zhong K. Alzheimer&#x2019;s disease drug development pipeline: 2018. Alzheimer&#x2019;s Dement. Transl.Res. Clin. Interv. 2018;4:195&#x2013;214. doi: 10.1016/j.trci.2018.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2018.03.009</ArticleId><ArticleId IdType="pmc">PMC6021548</ArticleId><ArticleId IdType="pubmed">29955663</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao J., Xu F., Davis J., Otte-H&#xf6;ller I., Verbeek M.M., Van Nostrand W.E. Cerebral Microvascular Amyloid &#x3b2; Protein Deposition Induces Vascular Degeneration and Neuroinflammation in Transgenic Mice Expressing Human Vasculotropic Mutant Amyloid &#x3b2; Precursor Protein. Am. J. Pathol. 2005;167:505&#x2013;515. doi: 10.1016/S0002-9440(10)62993-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)62993-8</ArticleId><ArticleId IdType="pmc">PMC1603574</ArticleId><ArticleId IdType="pubmed">16049335</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft J.M., Watterson D.M., Van Eldik L.J. Human amyloid &#x3b2;-induced neuroinflammation is an early event in neurodegeneration. Glia. 2006;53:484&#x2013;490. doi: 10.1002/glia.20306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.20306</ArticleId><ArticleId IdType="pubmed">16369931</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis E.K., Rasmussen A.L., Bennett W., King A., West A.K., Chung R.S., Chuah M.I. Microglia and motor neurons during disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis: Changes in arginase1 and inducible nitric oxide synthase. J. Neuroinflamm. 2014;11:55. doi: 10.1186/1742-2094-11-55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-11-55</ArticleId><ArticleId IdType="pmc">PMC3994340</ArticleId><ArticleId IdType="pubmed">24655927</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohgomori T., Yamasaki R., Takeuchi H., Kadomatsu K., Jinno S., Kira J.-I. Differential activation of neuronal and glial STAT3 in the spinal cord of theSOD1G93Amouse model of amyotrophic lateral sclerosis. Eur. J. Neurosci. 2017;46:2001&#x2013;2014. doi: 10.1111/ejn.13650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejn.13650</ArticleId><ArticleId IdType="pubmed">28715117</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty M.J., Noakes P.G., Bellingham M.C. Motor Cortex Layer V Pyramidal Neurons Exhibit Dendritic Regression, Spine Loss, and Increased Synaptic Excitation in the Presymptomatic hSOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis. J. Neurosci. 2015;35:643&#x2013;647. doi: 10.1523/JNEUROSCI.3483-14.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3483-14.2015</ArticleId><ArticleId IdType="pmc">PMC6605367</ArticleId><ArticleId IdType="pubmed">25589758</ArticleId></ArticleIdList></Reference><Reference><Citation>An T., Shi P., Duan W., Zhang S., Yuan P., Li Z., Wu D., Xu Z., Li C., Guo Y. Oxidative Stress and Autophagic Alteration in Brainstem of SOD1-G93A Mouse Model of ALS. Mol. Neurobiol. 2014;49:1435&#x2013;1448. doi: 10.1007/s12035-013-8623-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-013-8623-3</ArticleId><ArticleId IdType="pubmed">24390572</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomonov Y., Hadad N., Levy R. Reduction of cytosolic phospholipase A2&#x3b1; upregulation delays the onset of symptoms in SOD1G93A mouse model of amyotrophic lateral sclerosis. J. Neuroinflamm. 2016;13:1&#x2013;12. doi: 10.1186/s12974-016-0602-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0602-y</ArticleId><ArticleId IdType="pmc">PMC4888471</ArticleId><ArticleId IdType="pubmed">27250836</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang N., Leithold L.H.E., Post J., Ziehm T., Mauler J., Gremer L., Cremer M., Schartmann E., Shah N.J., Kutzsche J., et al. Preclinical Pharmacokinetic Studies of the Tritium Labelled D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer&#xb4;s Disease. PLOS ONE. 2015;10:e0128553. doi: 10.1371/journal.pone.0128553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0128553</ArticleId><ArticleId IdType="pmc">PMC4457900</ArticleId><ArticleId IdType="pubmed">26046986</ArticleId></ArticleIdList></Reference><Reference><Citation>Leithold L.H.E., Jiang N., Post J., Ziehm T., Schartmann E., Kutzsche J., Shah N.J., Breitkreutz J., Langen K.-J., Willuweit A., et al. Pharmacokinetic Properties of a Novel d-Peptide Developed to be Therapeutically Active Against Toxic &#x3b2;-Amyloid Oligomers. Pharm. Res. 2015;33:328&#x2013;336. doi: 10.1007/s11095-015-1791-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-015-1791-2</ArticleId><ArticleId IdType="pubmed">26381279</ArticleId></ArticleIdList></Reference><Reference><Citation>Schartmann E., Schemmert S., Ziehm T., Leithold L.H.E., Jiang N., Tusche M., Shah N.J., Langen K.-J., Kutzsche J., Willbold D., et al. Comparison of blood-brain barrier penetration efficiencies between linear and cyclic all-d-enantiomeric peptides developed for the treatment of Alzheimer&#x2019;s disease. Eur. J. Pharm. Sci. 2018;114:93&#x2013;102. doi: 10.1016/j.ejps.2017.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2017.12.005</ArticleId><ArticleId IdType="pubmed">29225107</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S., Haller E., Saporta S., Kolomey I., Nicosia S.V., Sanberg P.R. Ultrastructure of blood&#x2013;brain barrier and blood&#x2013;spinal cord barrier in SOD1 mice modeling ALS. Brain Res. 2007;1157:126&#x2013;137. doi: 10.1016/j.brainres.2007.04.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2007.04.044</ArticleId><ArticleId IdType="pubmed">17512910</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S., Saporta S., Haller E., Kolomey I., Bennett S.P., Potter H., Sanberg P.R. Evidence of Compromised Blood-Spinal Cord Barrier in Early and Late Symptomatic SOD1 Mice Modeling ALS. PLOS ONE. 2007;2:e1205. doi: 10.1371/journal.pone.0001205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0001205</ArticleId><ArticleId IdType="pmc">PMC2075163</ArticleId><ArticleId IdType="pubmed">18030339</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q.-X., Mok S.S., Laughton K.M., McLean C.A., Volitakis I., Cherny R.A., Cheung N.S., White A.R., Masters C.L. Overexpression of A&#x3b2; is associated with acceleration of onset of motor impairment and superoxide dismutase 1 aggregation in an amyotrophic lateral sclerosis mouse model. Aging Cell. 2006;5:153&#x2013;165. doi: 10.1111/j.1474-9726.2006.00200.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1474-9726.2006.00200.x</ArticleId><ArticleId IdType="pubmed">16626394</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu L.S., Anderton R.S., Cross J.L., Clark V.W., Knuckey N.W., Meloni B.P. Poly-arginine Peptide R18D Reduces Neuroinflammation and Functional Deficits Following Traumatic Brain Injury in the Long-Evans Rat. Int. J. Pept. Res. Ther. 2019;25:1563&#x2013;1572. doi: 10.1007/s10989-018-09799-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10989-018-09799-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu L.S., Anderton R.S., Knuckey N.W., Meloni B.P. The neuroprotective potential of arginine-rich peptides for the acute treatment of traumatic brain injury. Expert Rev. Neurother. 2016;16:361&#x2013;363. doi: 10.1586/14737175.2016.1150180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737175.2016.1150180</ArticleId><ArticleId IdType="pubmed">26840929</ArticleId></ArticleIdList></Reference><Reference><Citation>Meloni B.P., Milani D., Edwards A.B., Anderton R.S., Doig R.L.O., Fitzgerald M., Palmer T.N., Knuckey N.W. Neuroprotective peptides fused to arginine-rich cell penetrating peptides: Neuroprotective mechanism likely mediated by peptide endocytic properties. Pharmacol. Ther. 2015;153:36&#x2013;54. doi: 10.1016/j.pharmthera.2015.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2015.06.002</ArticleId><ArticleId IdType="pubmed">26048328</ArticleId></ArticleIdList></Reference><Reference><Citation>Fugere M., Appel J., Houghten R.A., Lindberg I., Day R. Short polybasic peptide sequences are potent inhibitors of PC5/6 and PC7: Use of positional scanning-synthetic peptide combinatorial libraries as a tool for the optimization of inhibitory sequences. Mol. Pharmacol. 2007;71:323&#x2013;332. doi: 10.1124/mol.106.027946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.106.027946</ArticleId><ArticleId IdType="pubmed">17012622</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada M., Hayashi H., Yuuki M., Matsushima N., Yuan B., Takagi N. Furin inhibitor protects against neuronal cell death induced by activated NMDA receptors. Sci. Rep. 2018;8:5212. doi: 10.1038/s41598-018-23567-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-23567-0</ArticleId><ArticleId IdType="pmc">PMC5980093</ArticleId><ArticleId IdType="pubmed">29581474</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaper S.D., Debetto P., Giusti P. The P2X 7 purinergic receptor: From physiology to neurological disorders. FASEB J. 2009;24:337&#x2013;345. doi: 10.1096/fj.09-138883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.09-138883</ArticleId><ArticleId IdType="pubmed">19812374</ArticleId></ArticleIdList></Reference><Reference><Citation>Yiangou Y., Facer P., Durrenberger P., Chessell I.P., Naylor A., Bountra C., Banati R.R., Anand P. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 2006;6:12. doi: 10.1186/1471-2377-6-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-6-12</ArticleId><ArticleId IdType="pmc">PMC1413551</ArticleId><ArticleId IdType="pubmed">16512913</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Ambrosi N., Finocchi P., Apolloni S., Cozzolino M., Ferri A., Padovano V., Pietrini G., Carr&#xec; M.T., Volont&#xe9; C. The Proinflammatory Action of Microglial P2 Receptors Is Enhanced in SOD1 Models for Amyotrophic Lateral Sclerosis. J. Immunol. 2009;183:4648&#x2013;4656. doi: 10.4049/jimmunol.0901212.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0901212</ArticleId><ArticleId IdType="pubmed">19734218</ArticleId></ArticleIdList></Reference><Reference><Citation>Allan S.M., Rothwell N.J. Cytokines and acute neurodegeneration. Nat. Rev. Neurosci. 2001;2:734&#x2013;744. doi: 10.1038/35094583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35094583</ArticleId><ArticleId IdType="pubmed">11584311</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari D., Chiozzi P., Falzoni S., Hanau S., Di Virgilio F. Purinergic Modulation of Interleukin-1&#x3b2; Release from Microglial Cells Stimulated with Bacterial Endotoxin. J. Exp. Med. 1997;185:579&#x2013;582. doi: 10.1084/jem.185.3.579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.185.3.579</ArticleId><ArticleId IdType="pmc">PMC2196027</ArticleId><ArticleId IdType="pubmed">9053458</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller C.M., Zakrzewski A.M., Ikin R.J., Boulter N.R., Katrib M., Lees M.P., Fuller S.J., Wiley J.S., Smith N.C. Dysregulation of the inflammatory response to the parasite, Toxoplasma gondii, in P2X7 receptor-deficient mice. Int. J. Parasitol. 2011;41:301&#x2013;308. doi: 10.1016/j.ijpara.2010.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpara.2010.10.001</ArticleId><ArticleId IdType="pubmed">21044631</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Ruiz C., Garc&#xed;a-Magro N., Negredo P., Avenda&#xf1;o C., Bhattacharya A., Ceusters M., Garc&#xed;a A.G. Chronic administration of P2X7 receptor antagonist JNJ-47965567 delays disease onset and progression, and improves motor performance in ALS SOD1G93A female mice. Dis. Model. Mech. 2020;13:dmm045732. doi: 10.1242/dmm.045732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.045732</ArticleId><ArticleId IdType="pmc">PMC7648608</ArticleId><ArticleId IdType="pubmed">33174532</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunkelmann T., Schemmert S., Honold D., Teichmann K., Butzk&#xfc;ven E., DeMuth H.-U., Shah N.J., Langen K.-J., Kutzsche J., Willbold D., et al. Comprehensive Characterization of the Pyroglutamate Amyloid-&#x3b2; Induced Motor Neurodegenerative Phenotype of TBA2.1 Mice. J. Alzheimer&#x2019;s Dis. 2018;63:115&#x2013;130. doi: 10.3233/JAD-170775.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-170775</ArticleId><ArticleId IdType="pmc">PMC5900553</ArticleId><ArticleId IdType="pubmed">29578479</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadros M.A., Harris B.M., Anderson W.B., Brichta A.M., Graham B.A., Callister R.J. Are all spinal segments equal: Intrinsic membrane properties of superficial dorsal horn neurons in the developing and mature mouse spinal cord. J. Physiol. 2012;590:2409&#x2013;2425. doi: 10.1113/jphysiol.2012.227389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2012.227389</ArticleId><ArticleId IdType="pmc">PMC3424761</ArticleId><ArticleId IdType="pubmed">22351631</ArticleId></ArticleIdList></Reference><Reference><Citation>Hugnot J.-P. Isolate and Culture Neural Stem Cells from the Mouse Adult Spinal Cord. Adv. Struct. Saf. Stud. 2013;1059:53&#x2013;63. doi: 10.1007/978-1-62703-574-3_5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-62703-574-3_5</ArticleId><ArticleId IdType="pubmed">23934833</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira T., Rasband W. The Image J User Guide.  [(accessed on 21 January 2021)];2011  Available online:  https://imagej.net/docs/guide/146.html.</Citation></Reference><Reference><Citation>McQuin C., Goodman A., Chernyshev V., Kamentsky L., Cimini B.A., Karhohs K.W., Doan M., Ding L., Rafelski S.M., Thirstrup D., et al. CellProfiler 3.0: Next-generation image processing for biology. PLoS Biol. 2018;16:e2005970. doi: 10.1371/journal.pbio.2005970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.2005970</ArticleId><ArticleId IdType="pmc">PMC6029841</ArticleId><ArticleId IdType="pubmed">29969450</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P.T., Wright K., Saad I., Mueller R., Morgan D., et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 1998;4:97&#x2013;100. doi: 10.1038/nm0198-097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0198-097</ArticleId><ArticleId IdType="pubmed">9427614</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster B., Hansen L., Adame A., Crews L., Torrance M., Thal L., Masliah E. Astroglial Activation of Extracellular-Regulated Kinase in Early Stages of Alzheimer Disease. J. Neuropathol. Exp. Neurol. 2006;65:142&#x2013;151. doi: 10.1097/01.jnen.0000199599.63204.6f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.jnen.0000199599.63204.6f</ArticleId><ArticleId IdType="pubmed">16462205</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang I.K., Choi J.H., Li H., Yoo K.-Y., Kim D.W., Lee C.H., Yi S.S., Seong J.K., Lee I.S., Yoon Y.S., et al. Changes in Glial Fibrillary Acidic Protein Immunoreactivity in the Dentate Gyrus and Hippocampus Proper of Adult and Aged Dogs. J. Veter. Med. Sci. 2008;70:965&#x2013;969. doi: 10.1292/jvms.70.965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1292/jvms.70.965</ArticleId><ArticleId IdType="pubmed">18840972</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>